First Human Dose Study of Anti-IL-20 in Psoriasis: A Study of Safety, Tolerability and Early Signals of Biologic and Clinical Effects

NCT01261767 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
55
Enrollment
INDUSTRY
Sponsor class

Stopped Trial discontinued due to apparent lack of response in psoriasis measures. No safety concerns were present

Conditions

Interventions

Sponsor

Novo Nordisk A/S